Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that immunocompromised people with conditions that render them more vulnerable to covid-19 have timely access to effective (a) protective drugs and (b) support measures.

Since June 2023, the pathway for COVID-19 treatments has been delegated from the former national pandemic-specific arrangements to more routine local arrangements for assessment and treatment. Integrated care boards are now responsible for ensuring that local health systems understand local pathways and how to refer patients for assessment and treatment. Information on treatments for COVID-19 is available at the following link:

https://www.nhs.uk/conditions/covid-19/treatments-for-covid-19/

This autumn, individuals who are immunocompromised or otherwise at high risk will receive booster vaccinations, following the recommendations of the Joint Committee on Vaccination and Immunisation. The UK Health Security Agency supports engagement within its remit with the voluntary and community sector, including through the Voluntary, Community, and Social Enterprise Health and Wellbeing Alliance, the Immunocompromised Coalition, and organisations representing inclusion health groups.